NCT07408804 Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
| NCT ID | NCT07408804 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bangladesh Medical University |
| Condition | Unresectable Hepatocellular Carcinoma (HCC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-04-08 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-04-08 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma. The study aims to determine whether the addition of TACE to lenvatinib results in improved tumor response compared with lenvatinib alone in a real-world clinical setting.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years, 2. Hepatocellular carcinoma, confirmed by dynamic CT scan / MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment, 3. At least one measurable lesion based on mRECIST criteria, 4. ECOG performance status 0-2, Exclusion Criteria: 1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement, 2. Hepatocellular carcinoma with main trunk portal vein thrombosis, 3. Child Turcotte Pugh Score 10 ( C) or more, 4. ALBI grade 3, 5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event, 6. Known allergy or intolerance to lenvatinib .
Contact & Investigator
Md. Ayub Al Mamun, FCPS (Medicine)
STUDY CHAIR
Frequently Asked Questions
Who can join the NCT07408804 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Unresectable Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07408804 currently recruiting?
Yes, NCT07408804 is actively recruiting participants. Contact the research team at drsouravhepato@gmail.com for enrollment information.
Where is the NCT07408804 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh.
Who is sponsoring the NCT07408804 clinical trial?
NCT07408804 is sponsored by Bangladesh Medical University. The principal investigator is Md. Ayub Al Mamun, FCPS (Medicine). The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.